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บทคดัยอ่ 
วตัถปุระสงค:์ เพื่อประเมนิความคงตวัทางเคมขีองยา Meronem® (meropenem 
trihydrate) ตามความเขม้ขน้ทีใ่ช้โดยทัว่ไป ใน 3 อุณหภูม ิณ เวลาต่าง ๆ วิธี
การศึกษา: น าผลติภณัฑ์ยา Meronem® ชนิดฉีด  (บรษิทั Astra Zeneca) ละ
ละลายดว้ย 0.9% sodium chloride  ใน PVC bags จนไดส้ารละลายความเขม้ขน้ 
10 และ 20 มลิลกิรมั/มลิลลิติร เก็บสารละลายดงักล่าวในตูค้วบคุมอุณหภูมทิี ่25, 
30 และ 35 องศาเซลเซยีส จากนัน้เกบ็ตวัอยา่งสารละลายมาวเิคราะหป์รมิาณดว้ย
วธิ ีHPLC ทีเ่วลา 0, 1, 2, 3, 4, 8 และ 12 ชัว่โมง แลว้พจิารณาความสมัพนัธ์
ระหว่างความคงตวัของยากบัอุณหภูมแิละความเขม้ขน้ทีเ่ปลีย่นแปลงไป โดยใช้
เกณฑ์ความคงตวัที่ 90% ของตวัยาที่เหลอื ผลการศึกษา: สารละลายยาฉีด 
Meronem® ความเขม้ขน้ 10 มลิลกิรมั/มลิลลิติร มคีวามคงตวัเป็นระยะเวลา 8 
ชัว่โมงที่อุณหภูม ิ25 องศาเซลเซียส แต่พบว่าความคงตวัดงักล่าวลดลงเมื่อ
อุณหภูมเิพิม่สูงขึ้น (4 ชัว่โมงที ่30 องศาเซลเซยีส และ 1 ชัว่โมงที ่35 องศา
เซลเซยีส) สว่นกรณคีวามเขม้ขน้ 20 มลิลกิรมั/มลิลลิติรพบวา่ยายงัคงตวัที ่< 8, 3 
และ < 1 ชัว่โมงทีอุ่ณหภมู ิ25, 30 และ 35 องศาเซลเซยีส ตามล าดบั สรปุ: ความ
คงตวัของผลติภณัฑย์า Meronem® ชนิดฉีดขึ้นกบัอุณหภูมแิละความเขม้ขน้ การ
เพิม่อุณหภูมแิละความเข้มขน้ของยาทีสู่งขึ้นจะท าใหค้วามคงตวัของยาลดต ่าลง 
ดงันัน้อุณหภูมิและความเข้มข้นของยาที่เหมาะสมจึงมีความส าคญัในกรณีที่
ตอ้งการหยดยาแบบยดืระยะเวลา (extended infusion)  
ค าส าคญั: ความคงตวั, มโีรพเีนม, การหยดยาแบบยดืระยะเวลา, อุณหภูม ,ิ 
ความเขม้ขน้   
Abstract 
Objective: To evaluate chemical stability of Meronem® (meropenem 
trihydrate) in two commonly used concentrations when stored in 3 
temperatures over time. Methods: Meronem® injection (Astra Zeneca) was 
used to prepare 10 mg/mL and 20 mg/mL of meropenem in 0.9% sodium 
chloride solution. The final solutions in PVC bags were stored at 25, 30, 
and 35 °C. The solutions were determined for concentration at 0, 1, 2, 3, 4, 
8 and 12 hours by means of HPLC analysis. The associations between 
drug stability, temperature and concentration were determined. Stability 
was set with a cut-off of 90%. Results: Meronem® 10 mg/mL solutions was 
stable for up to 8 hours at 25°C. Its stability was lower at higher 
temperatures, specifically, 4 hours at 30 °C and 1 hour at 35 °C. For 20 
mg/mL solutions, the solution was stable in < 8, 3 and < 1 hours at 25, 30 
and 35 °C, respectively. Conclusion: The stability of Meronem® injection 
solution was affected by temperature and concentration where high 
temperature and concentration resulted in less stability. Suitable 
temperature and drug concentration should be concerned when this drug is 
given by extended infusion.  
Keywords: stability, meropenem, extended infusion, temperature, 
concentration 
Introduction 
The multidrug-resistant gram-negative bacterial infection 
continues to rise in several regions worldwide.1,2 Meropenem 
is active against gram-negative pathogenic bacteria including 
multidrug-resistant gram-negative bacterial infection.3 The 
percentage of time above the MIC (%T > MIC) is the most 
important pharmacokinetic/pharmacodynamic (PK/PD) 
parameter correlating with therapeutic efficacy of 
meropenem, so extended or continuous infusion of 
meropenem is the key to success.4  
According to a previous study, the results suggested that 
extended infusion of 1 g (10 mg/mL) and 2 g (20 mg/mL) of 
meropenem could provide serum concentrations above the 
MIC of multidrug-resistant gram-negative pathogenic 
bacteria.5 Thus, the stability of meropenem in the extended 
infusion in the two concentrations (10 and 20 mg/mL) is 
important, especially when it is given at room temperature in 
tropical countries (32 to 37 °C).5,6 However, information 
about stability of meropenem in the extended infusion at high 
temperature and concentration used in clinical practice is 
limited. The objective of this study therefore was to evaluate 
the meropenem stability of the extended infusion in various 
concentrations and temperatures.  
 
Methods 
 
Drugs, chemicals and instruments  
Meropenem (1g/vial) as pure powder was from Astra 
Zeneca. Meropenem trihydrate as reference standard was a 
product of Fluka. Sodium chloride solution (0.9%) in PVC 
bag was a product of GHP, Thailand. Potassium dihydrogen 
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phosphate was obtained from BDH Laboratory Supplies. 
Orthophosphoric acid was from Merck. HPLC-grade 
acetonitrile and water were obtained from RCI Lab Scan, 
Thailand, and were used to prepare all solutions for the 
HPLC analysis.  
Instruments and analytical conditions were as follows. 
The HPLC machine was an LC-20AD Prominence model 
HPLC, Shimadzu, Japan, equipped with a model LC-20AD 
pump, a UV/Vis detector SPD-20A, a model SIL-20AHT 
autosampler, a model CTO-20AC column oven, a DGU-
20A5R degassing unit and an LC solution integrator 
(Shimadzu, Japan). The analyses were performed by using 
reverse-phase technique.7 A 5-m particle size C18 Fortis 
column with a dimension of 250 x 4.0 mm (Fortis 
Technologies) was used. Meropenem injection was eluted 
isocratically using a mobile phase consisting of 30 mM 
monobasic phosphate buffer and acetonitrile (90:10 v/v), 
adjusted to pH 3.0 with an orthophosphoric acid flow rate of 
1.0 ml/min. The UV/Vis detector was set at 298 nm. The 
mobile phase was prepared freshly, filtered through a 0.45-
mm membrane filter and degassed before use. The HPLC 
system was operated at 25 °C. An ESPEC’s temperature 
and humidity controller cabinet, LHL-112 model, was used to 
study under three temperature conditions.7  
 
Preparation of meropenem sample solution   
To prepare sample solutions at final concentrations of 20 
mg/mL and 10 mg/mL, meropenem 1 g/vial was diluted as 
follows. First, each 1-g vial was reconstituted with 10 mL of 
HPLC-grade water to yield a meropenem concentration of 
100 mg/mL. To prepare a final 20 mg/mL sample, two 
reconstituted vials (i.e. 2 g in 20 mL) were further diluted 
with 80 mL of 0.9% sodium chloride in a PVC bag. With the 
same method, one reconstituted vial (1 g in 10 mL) was 
further diluted with 90 mL of 0.9% sodium chloride in a PVC 
bag to prepare a final 10 mg/mL sample. A total of three 
replicate solutions were prepared for each concentration and 
temperature.  
Regarding temperature, prepared meropenem solutions 
in PVC bags were incubated at three controlled 
temperatures, specifically 25, 30 and 35 °C. A sample of 3 
mL of each incubated solution was collected at 0, 1, 2, 3, 4, 
8 and 12 hours and kept on ice until it was subject to 
analysis. At the analysis, all incubated samples with 
concentrations of 10 and 20 mg/ml were further diluted with 
HPLC-grade water to concentrations of 50 and 100 µg/mL, 
respectively. An aliquot of 20 μL was injected into the HPLC 
column. The concentration of injected sample was calculated 
from the calibration curve.  
  
Preparation of reference standard solution and 
calibration curve  
A total of 10 mg of meropenem reference standard was 
weighted accurately and added to a 10-mL volumetric flask 
and dissolved in HPLC grade water, as a stock solution. A 
0.1-mL aliquot of stock solution was diluted to 100 mL in 
HPLC grade water, and yielded a concentration of 20 µg/mL. 
The final concentrations of 20, 40, 60, 80, 100 and 120 
µg/mL were prepared by the dilution method previously 
described and used for plotting standard curves. The 
calibration curve was plotted between peak area against 
meropenem reference standard with concentrations of 20 to 
120 µg/mL. 
The analytical method for determining meropenem in the 
solution by HPLC method was the one of Mendeza et al.7 To 
verify the method, linearity, precision and accuracy of the 
calibration curve were determined with meropenem 
reference standard with concentrations ranging from 20 to 
120 µg/mL. The acceptance criteria of linearity, precision and 
accuracy were r2 > 0.998, % CV < 2% and mean recovery of 
98 - 102%, respectively.8,9   
 
Data analysis 
Results were reported as mean percentage with standard 
deviation of meropenem concentrations compared to that at 
the initial time point. Samples were considered stable if 
mean percentage of meropenem concentrations remained 
higher than 90% of the control (0 hour) according to the U.S. 
Pharmacopeia.10  
 
Results 
 
The calibration curve shows a linearity in the 
concentration range of 20 - 120 µg/mL, with r2 > 0.99. The 
standard curve between peak area and concentration is 
shown in Figure 1. The within-run precision (% CV) was in a 
range of 0.0 - 0.4% and the between-run precision ranged 
from 3.2% to 4.9%. The within-run accuracy was 96.13 - 
100.18% with the between-run accuracy of 97.18 - 100.18%.  
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Figure 1  Calibration curve for determining meropenem 
concentration, and peak area versus meropenem 
concentration demonstrating linearity.   
 
Stability of meropenem in 0.9% sodium chloride solution 
incubated at 25, 30 and 35 °C for up to 12 hours is shown in 
Figure 2 (meropenem 10 mg/mL) and Figure 3 (meropenem 
20 mg/mL). Based on a criterium of 90% remaining as being 
stable, meropenem at a concentration of 10 mg/mL was 
stable for 8 hours (90%) when stored at 25 °C. Shorter 
duration was found with higher temperature where the 
solution was stable at 4 hours (92%) and 1 hours (91%) 
when stored at 30 °C and 35 °C, respectively. For 
meropenem 20 mg/mL solution, the stable duration was 
shorter. After stored at 25 °C for 8 hours, while 90% of the 
10 mg/mL meropenem was found, only 87% of the 20 
mg/mL solution was detected. Similar to the 10 mg/mL 
meropenem solution, the higher the temperature, 30 °C and 
35 °C, the lower the stable duration of the 20 mg/mL 
solution, i.e. 3 hour (91%) and less than 1 hour (79%), 
respectively.  
 
 
 
Figure 2  Stability of 10 mg/mL meropenemin in 0.9% 
sodium chloride solution incubated at three different 
temperatures for up to 12 hours.  
 
 
Figure 3  Stability of 20 mg/mL meropenem in 0.9% 
sodium chloride solution incubated at three different 
temperatures for up to 12 hours. 
 
Discussions and Conclusion 
 
Based on our definition of stability, admixtures were 
stable if the mean percentages of meropenem remained 
greater than 90%. Meropenem 10 mg/mL solution was stable 
for 8, 4 and 1 hours at 25, 30 and 35 °C, respectively. In 
addition, 20 mg/mL solution was stable for < 8, 3 and < 1 
hours at 25, 30 and 35 °C, respectively.  
To achieve an adequate time above the MIC (%T > 
MIC), the extended infusion of meropenem has been 
recommended in clinical practice.11 The recommendation is 
however not free of limitation as the stability of meropenem 
solution was temperature and concentration-dependent. Our 
study found that the stability of reconstituted meropenem 
was lessened with higher temperature. A previous study by 
Berthoin et al12 indicated that 40 mg/mL meropenem in water 
for injection was degraded faster in a higher temperature 
where a 10% degradation was found in 12 hours when 
stored at 25 °C, but 6 hours at 37 °C. Furthermore, our 
finding that the degradation of meropenem was 
concentration-dependent were also supported by the works 
of Viaene et al and Franceschi et al.13,14 In these two 
studies, higher concentration of meropenem in water for 
injection resulted in a faster rate of degradation at 25C. 
This was evident as 10% degradation was found after 5 
hours in the high concentration of meropenem (64 mg/mL) 
and 8 hours in a low one (5 mg/mL).13,14 The study by Patel 
and colleagues also found that the stability of meropenem 
was influenced by the drug concentration.6 After stored at 4 
– 5 °C for 4 hours, more degradation (2.7%) was found in 
the 20 mg/mL meropenem in sterile water for injection, while 
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a less degradation (0.7%) in the 1 mg/mL solution.6 Although 
results from these studies agreed with the one in our study, 
concentrations tested in their studies were considerably 
different from ours.6,13,14  In our study, the concentrations of 
and solvents for meropenem were mostly identical to the 
ones in the real practice. In addition, our finding also 
suggested that at a high practical concentration (20 mg/mL) 
and a relatively high temperature (35 ºC) which could be 
found in most medical wards in tropical countries almost 
throughout the year, 10% degradation of meropenem was 
found as fast as after 1 hour.   
Based on this study and other studies,’ findings factors 
influencing the stability of meropenem in normal saline 
solution were drug higher concentration and higher 
temperature. Practically, when meropenem is given by 
extended infusion, we therefore recommend that it should be 
diluted to a low concentration (10 mg/mL) and infused in an 
air conditioned room (≤ 25 °C) if possible, especially in 
tropical countries.   
This study was no exception regarding limitations. First, 
this experiment was performed at the indicated 
temperatures, i.e. 25, 30, and 35 °C, so our results should 
not be extrapolated to out-of-range temperatures such as 
those less than 25 °C or greater than 35 °C. Moreover, 
based on a range of normal room temperature of 32 – 37 °C 
in tropical countries, we suggest more stability tests on 
higher temperature in further studies. Lastly, our results were 
based on the test of the product named Meronem® injection 
solution. Stability profiles of other various brands of 
meropenem for injection could be different attributable to 
differences in salts or other ingredients. Application of 
stability profile from this experiment to other brands of 
meropenem should be done with care, and studies on 
stabilities of other brands should also be done.   
 
Conclusions 
Meropenem solution for injection was less stable with 
higher temperature and concentration. Based on a 
pharmacokinetic/ pharmacodynamic profile of meropenem 
where adequate time above the MIC (%T > MIC) could be 
achieved by the extended infusion, we recommend that the 
solution should be diluted to the lowest possible 
concentration infused in a low temperature, such as in an air 
conditioned room.  
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